RxDoctor Payments Data

Jing Zhang

Dermatopathology · Columbia, SCNPI 1174582084

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 65.1% of it on its own, with 2 other manufacturers making up the rest.

$188in general payments, 2019–2025

Across 4 payments — averaging $46.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$122
  • Regeneron Healthcare Solutions, Inc.$43
  • Incyte Corporation$22

What the payments were for

  • Food & beverage$188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few dermatopathology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,072,250
Medicare patients
6,951
Services billed
15,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatopathology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →